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Abstract
Background: Upper urothelial cancer (UUC), i.e. transitional cell carcinomas of the renal pelvis
and the ureter, occur at an increased frequency in patients with hereditary nonpolyposis colorectal
cancer (HNPCC). Defective mismatch repair (MMR) specifically characterizes HNPCC-associated
tumors, but also occurs in subsets of some sporadic tumors, e.g. in gastrointestinal cancer and
endometrial cancer.
Methods: We assessed the contribution of defective MMR to the development of UUC in a
population-based series from the southern Swedish Cancer Registry, through microsatellite
instability (MSI) analysis and immunohistochemical evaluation of expression of the MMR proteins
MLH1, PMS2, MSH2, and MSH6.
Results: A MSI-high phenotype was identified in 9/216 (4%) successfully analyzed patients and a
MSI-low phenotype in 5/216 (2%). Loss of MMR protein immunostaining was found in 11/216 (5%)
tumors, and affected most commonly MSH2 and MSH6.
Conclusion: This population-based series indicates that somatic MMR inactivation is a minor
pathway in the development of UUC, but tumors that display defective MMR are, based on the
immunohistochemical expression pattern, likely to be associated with HNPCC.
Background
Upper urothelial carcinomas (UUC) represent about 5%
of the urinary tract tumors, with transitional cell carcino-
mas of the renal pelvis and the ureter being the most com-
mon [1]. Exogenous agents such as smoking and
occupational exposures to e.g. acrylamines constitute risk
factors that are estimated to cause up to half of the tumors
[2]. Hereditary factors also contribute to the development
of UUC with a 2-fold increased risk among first-degree rel-
atives [3]. The familial cases develop due to site-specific
inheritance as well as within the hereditary nonpolyposis
colorectal cancer (HNPCC) syndrome [1,3-5]. Individuals
with HNPCC are at increased risk for several types of can-
cer, with the highest life-time risks for colorectal cancer
(80%), endometrial cancer (40–60%), ovarian cancer
(10–15%), cancer of the small intestine and upper urothe-
lial cancer [4], and the revised Amsterdam criteria for the
diagnosis of HNPCC consider these tumor types to be
associated with the syndrome [6]. Although HNPCC-
patients have a 14 to 75-fold increased risk of UUC, with
the highest risks reported for carriers of mutations in
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MSH2, the absolute lifetime risk for mutation carriers to
develop UUC is <10% [7-9].
HNPCC is caused by a germline mutation in a DNA mis-
match-repair (MMR) gene, most commonly affecting
either of the genes MLH1 (40%), MSH2 (50%) or MSH6
(10%) [10,11]. Over 95% of the HNPCC-tumors are char-
acterized by wide-spread microsatellite instability (MSI)
and 90% by loss of immunohistochemical expression of
the MMR protein affected [12]. Hence, these analyses are
used in the clinical diagnosis of suspected HNPCC cases.
However, somatic MMR defects occur in a subset of cer-
tain sporadic tumor types, e.g. in 15–20% of gastrointes-
tinal and endometrial cancer, and are in most of these
tumors caused by somatic hypermethylation of the MLH1
promoter [13,14].
Studies of the contribution of defective MMR to the devel-
opment of urothelial carcinomas, assessed using MSI
analysis, loss of MMR protein expression, and MMR gene
mutations, have found a low frequency (<10%) of MMR
defects in urothelial carcinomas of the urinary bladder
[15], but have indicated a high frequency (15–45%) of
MMR defects in UUC [16-19]. Since data on the frequency
of MMR defects in UUC are scarce and in order to charac-
terize the contribution of the different MMR proteins to
development of UUC, we assessed MSI and immunohis-
tochemical expression of MLH1, MSH2, and MSH6 in a
population-based series of UUC.
Methods
Patient Material
In Sweden a population-based national Cancer Registry
was started in 1958 and applies mandatory registration by
both clinicians and pathologists in order to achieve maxi-
mal coverage (estimated to be 98%). We applied the
southern Swedish part of the registry, which currently con-
tains about 300.000 entries, to identify all carcinomas of
the upper urothelial tract that had developed between
1992 and 1999. We identified 262 patients with a median
age of 70 (range 34–90) years and a male:female ratio of
1.8:1. For further analyses, 27 patients were excluded
because of lack of tumor blocks, and 19 because of
autopsy-based diagnosis with autolysis that prevented
good quality immunostaining. Hence, 216 patients with a
median age of 69 (range 34–89) years were analyzed.
Tumor location was as follows for the whole material
(cases analyzed within parenthesis): renal pelvis 173
(154), ureter 75 (60) and an unspecified tumor location
in 14 (2) patients. Data on family history of cancer or
blood samples for mutation analysis were not available
since the study was retrospective and register-based. Ethi-
cal approval for the study was obtained from the ethics
committee at Lund University.
Analysis of microsatellite instability (MSI)
Representative tumor blocks containing at least 20%
tumor tissue were selected and DNA was extracted from 3
× 10-µm sections of formalin-fixed, paraffin-embedded
tissue through incubation of the samples in EDTA-Tris-
buffer with Proteinase K at 65°C for at least 2 hours, fol-
lowed by boiling, centrifugation, and removal of the
aqueous phase, which was stored at 4°C. MSI was
assessed with the National Cancer Institute (NCI) panel;
BAT25, BAT26, BAT34, BAT40, D2S123 and D5S346 [20].
These markers identify MSI with high accuracy in colorec-
tal cancer, but the sensitivity of individual markers may
vary between different tumor types [21]. The primer
sequences used have been reported previously [22]. The
markers were fluorescencely-labeled as follows: NED™
(yellow) for BAT25, 6-FAM™ (blue) for BAT26, BAT34C4
and D2S123, and HEX™ (green) for BAT40 and D5S346.
The DNA microsatellite sequences were amplified by PCR
according to the following programme; 94°C for 7 min-
utes, 10 × (94°C for 15 seconds, 45°C (BAT 25) / 50°C
(other markers) for 15 seconds, and 72°C for 15 sec-
onds), 23 × (89°C for 15 seconds, 45°C / 50°C for 15 sec-
onds, and 72°C for 15 seconds), 72°C for 7 minutes,
followed by a final cooling step at 4°C. 0.5–2 µl PCR
product was mixed with 12 µl deionized formamide (Hi-
Di Formamide, Applied Biosystems) and 0.5 µl ROX™ 500
Size Standard (Applied Biosystems), denatured at 95°C
for 2 minutes, chilled on ice, and separated in Perform-
ance Optimized Polymer-4 (POP-4™) on the ABI PRISM™
3100 Genetic Analyzer (Applied Biosystems) for fragment
analysis. MSI was defined by the presence of extra peaks
demonstrating altered length of the repetitive sequence.
Data from at least three markers were required for the clas-
sification of tumors as microsatellite stable (MSS). The
tumors were regarded as MSI-high if at least two microsat-
ellites showed instability and as MSI-low if only one
marker showed instability. All cases with suspected MSI
were verified through repeated analysis.
Immunohistochemistry
Immunohistochemical staining was performed using 4-
µm sections of formaline fixed, paraffin-embedded tissue,
which were mounted on DAKO ChemMate Capillary Gap
Microscope Slides (DAKO A/S BioTek Solutions, USA)
and dried at room temperature overnight followed by
incubation at 60°C for 1–2 hours. The tissue sections
were deparaffinized in xylol and rehydrated through
descending concentrations of alcohol. Antigen retrieval
was achieved by microwave-treatment in 1 mM EDTA, pH
9.0, at 900 W for 8 minutes followed by 15 minutes at 350
W. The slides were then allowed to cool for at least 20
minutes in the EDTA-solution. Immunohistochemical
staining was performed in an automated immunostainer
(TechMate 500 Plus, DAKO), according to the manufac-
turers instructions. The main steps were as follows: MouseBMC Cancer 2005, 5:23 http://www.biomedcentral.com/1471-2407/5/23
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monoclonal IgG antibodies to MLH1 (clone G168-15,
dilution 1:100, PharMingen, San Diego, CA, USA) MSH2
(clone FE-11, dilution 1:100, Oncogene research prod-
ucts, Boston, MA, USA), MSH6 (clone 44, dilution
1:1000, BD Transduction Laboratories) and PMS2
(clone:A16-4, dilution 1:500, BD Pharmingen) were
applied and the sections were incubated at room temper-
ature for 25 minutes.
Thereafter, the slides were incubated with biotinylated
anti-mouse antibody (DAKO) for 25 minutes (for MLH1
and MSH2) or with rabbit anti-mouse immunoglobulins
(DAKO, dilution 1:400) for 20 min (for MSH6 and
PMS2). Endogenous peroxidase activity was blocked in
Peroxidase-blocking solution (DAKO) for 3 × 2,5 min-
utes. This was followed by incubation with streptavidin-
horseradish peroxidase for 25 minutes for MLH1 and
MSH2, whereas EnVision™/HRP rabbit/mouse (DAKO)
incubation for 25 min was used for MSH6 and PMS2.
Finally, the tissue sections were treated with diaminoben-
zidine (DAB) for 3 times 5 min, counterstained with
hematoxylin for 1 min, rinsed in running tap water for 10
min, dehydrated in ascending concentrations of alcohol
and mounted. After each step, the sections were rinsed in
Tris buffered saline, pH 7.4, and Tween-20. In order to
block nonspecific protein binding, bovine serum albumin
was added to the buffer before the antibody incubation
steps in the MLH1 and MSH2 stainings. A detailed proto-
col is available from the authors upon request. Two of the
authors (K.E. and M.N.), who were blinded regarding the
MSI status, independently evaluated all stained sections.
Sections without nuclear staining in the tumor cells, in the
presence of normal nuclear staining in lymphocytes and
normal epithelial or stromal cells in the same section,
were considered to have a lost expression (Fig. 1). The
expression was classified as present, absent or non-evalu-
able without grading of the staining intensity.
Results
Microsatellite analysis
For the MSI analysis of the 216 cases, 16 tumors were
excluded because of small tumor size or less than 20%
tumor tissue in the samples, and 6 tumors were excluded
because of lack of information from at least 3 MSI mark-
ers, which left 194 tumors successfully analyzed. A MSS
phenotype was identified in 180 tumors, MSI-low in 5,
and MSI-high in 9 tumors (table 1, figure 1).
Immunohistochemistry
Immunohistochemical staining for the MMR proteins
gave evaluable results for MLH1 in 211 tumors, MSH2 in
216, MSH6 in 200 tumors and PMS2 in 215 tumors. Of
the 180 MSS tumors, 177 showed retained expression for
all evaluable proteins, as did also the 5 MSI-low tumors.
One MSS tumor that was not assessed for MSI due to a
small amount of tumor material, showed loss of MSH2
and MSH6 expression, one MSS tumor showed loss of
MLH1 and PMS2, one MSS tumor showed loss of MSH6
expression, and one MSS tumor showed loss of MSH2
expression. Among the 9 MSI-high tumors, 5 showed a
concomitant loss of expression of MSH2 and MSH6, 1
tumor showed loss of expression of MSH6 and 1 tumor
showed loss of expression of MLH1 and PMS2. Retained
expression of all four proteins was found in 2 MSI-high
tumors of the renal pelvis (table 1, figure 2).
Synchronous and metachronous tumors
Eleven patients had developed synchronous tumors of the
upper urinary tract, and these cases were all analyzed. In
one patient with synchronous urethral tumors the tumor
tissue showed MSI and loss of expression of MLH1 in
both tumors (U2-229), and the other patients with syn-
chronous tumors had MSS tumors all of which showed
retained expression of all three MMR proteins (table 1).
Metachronous UUC occurred in 3/262 patients, 2 of
whom were included in the series analyzed, and these
tumors were MSS and MSI-low, respectively, but both
tumors showed retained MMR protein expression.
In the whole series, 122 (97 among the analyzed cases)
patients had been diagnosed with another malignancy,
which was bladder cancer in 67 cases (54 among the cases
analyzed). Among the cases with MSI and/or immunohis-
tochemical MMR protein loss, 8 metachronous tumors
developed and 5/5 analyzed (a leiomyosarcoma, a colon
tumor, an endometrial cancer and 2 bladder tumors) dis-
played MSI and immunohistochemical loss of the con-
cordant MMR protein (table 1).
Discussion
Urothelial carcinomas of the upper and the lower urothe-
lial tract share many clinical and epidemiological traits.
However, the UUC have specifically been associated with
HNPCC, and in line with this observation the contribu-
tion of defective MMR has been reported to differ between
these tumor types. In bladder cancer, a MSI-high pheno-
type has been found in 3–10% of the tumors [15,23],
whereas elevated microsatellite alterations at selected
tetranucleotides (EMAST) has been described at a higher
rate in bladder cancer and the latter phenomenon is being
perused as a tumor marker in urine [24]. Higher MSI rates
have been reported in UUC with 13–31% of the tumors
showing MSI [16-19]. A similar anatomical specificity has
been described in the ventricle with a higher number of
MSI tumors in the antrum, and in the colorectum with
20% MSI tumors in the cecum and <5% in the rectum [25-
27].BMC Cancer 2005, 5:23 http://www.biomedcentral.com/1471-2407/5/23
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We applied the population-based southern Swedish Can-
cer Registry to assess the contribution of defective MMR to
the development of UUC. The results are based on 216/
262 (82%) of the tumors that occurred in the southern
Sweden health care region between 1992 and 1999. A
MSI-high phenotype was found in 9/216 (4%) patients
and a MSI-low phenotype in 5/216 (2%). In 11/216 cases
synchronous tumors occurred within the urothelial tract
and 1 patient (U2-229) had synchronous MSI-high
tumors, all of which displayed a concordant immunohis-
tochemical loss of MLH1. Thus, the vast majority of syn-
chronous UUC does not display MMR defects and does
not develop within the HNPCC syndrome. The overall fre-
quency of MSI tumors detected in our study, 4%, is lower
than the 13–31% previously reported (table 2) [16-19].
Possible reasons for the discrepancy include that our
study was unselected and population-based. Furthermore,
Müller et al. [28] have suggested that microsatellite insta-
Microsatellite instability in case RP8-626 where the MSI-curves show instability with 1–2 additional peaks for the markers  BAT25, BAT26 and BAT34 and larger size variation for the markers BAT40, D2S123 and D5S346 Figure 1
Microsatellite instability in case RP8-626 where the MSI-curves show instability with 1–2 additional peaks for the markers 
BAT25, BAT26 and BAT34 and larger size variation for the markers BAT40, D2S123 and D5S346.
BAT25
BAT26
BAT34
D2S123
D5S346
BAT40BMC Cancer 2005, 5:23 http://www.biomedcentral.com/1471-2407/5/23
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bility analysis should optimally be performed by using
microdissection, where analysis is made on DNA
extracted from tumor cells without dilution of DNA from
normal cells. However, this was not available at our insti-
tution at the time the study. The marker selection is prob-
ably not the cause of discrepancy since the NCI marker
panel for MSI analysis has proven effective in several
extracolonic tumor types such as endometrial, ovarian
and gastric cancer [20,29]. Hartmann et al. [18] identified
BAT40 (93% detection rate) and BAT25 (53%) as the best
markers for the detection of MSI also in UUC and indeed
reported that using a combination of the markers BAT40,
BAT25, and BAT26 allowed identification of all MSI
tumors. Whereas our finding of 5% MMR defects in renal
pelvis tumors is in accordance with the 5–8% previously
reported, we identified MMR defects in a lower (4%) frac-
tion of the urethral tumors than the 25–41% previously
reported [16-19,23].
Table 1: Clinicopathological data of MMR-defective tumors
Case no. Sex / Age Tumor location 
(Synchron./Metachron.)
WHO-Grade Stage Instable 
markers
Immunohistochemical expression
MLH1 MSH2 MSH6 PMS2
U1-113 F/54 ureter G2 pTX NE + - - +
53 endometrium (M) 4/6 + - - +
U2-229 F/57 ureter G2 pT1 4–5/6 - + + -
57 ureter (S) 4–5/6 - + + -
U3-821 M/61 ureter* G2 pT1 2–3/6 + - - +
RP1-101 M/60 renal pelvis G2 pT3 3/5 + - - +
43 sarcoma (M) 3/4 + - - +
53 colon (M) 1/6¤ + - - +
RP2-131 M/75 renal pelvis G3 pT4 2/6 + + + +
RP3-119 F/69 renal pelvis G3 pTa 0/6 - + NE -
RP4-267 F/67 renal pelvis G2 pT1 5/5 + - - +
70 urinary bladder (M) 3/4 + - - +
RP5-401 M/56 renal pelvis G2 pTa 0/6 + + - +
RP6-528 F/87 renal pelvis G2 pT1 2/5 + + + +
87 urinary bladder (S) 0/6 + + + +
RP7-613 F/57 renal pelvis^ G2 pT1 3/6 + + - +
54 urinary bladder (M) 4/6 + - - +
RP8-626 M/66 renal pelvis G3 pT2 6/6 + - - +
RP9-701 F/49 renal pelvis# G2 pTa 0/5 + - NE +
RP10-809 F/82 renal pelvis G3 pT4 4/4 + - - +
¤Positive for BAT26
* Myelofibrosis at the age of 67 years.
^Cervical cancer at the age of 33.
# Rectal tumor at the age of 38.
G2 moderately differentiated
G3 poorly differentiatedBMC Cancer 2005, 5:23 http://www.biomedcentral.com/1471-2407/5/23
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Immunohistochemical staining for the MMR proteins shows loss of nuclear expression for MLH1 and PMS2 and retained  expression of MSH2 and MSH6 in case U2-229, and loss of MSH2 and MSH6 with retained expression of MLH1 and PMS2 in  case RP8-626 Figure 2
Immunohistochemical staining for the MMR proteins shows loss of nuclear expression for MLH1 and PMS2 and retained 
expression of MSH2 and MSH6 in case U2-229, and loss of MSH2 and MSH6 with retained expression of MLH1 and PMS2 in 
case RP8-626.
MLH1
PMS2
MSH6
MSH2
RP8-626 U2-229BMC Cancer 2005, 5:23 http://www.biomedcentral.com/1471-2407/5/23
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Loss of immunostaining was in our series detected in 7/9
MSI-high tumors, in one tumor biopsy that was to small
to allow MSI analysis, and in 2 MSS tumors (figure 2). The
immunohistochemical expression loss affected MSH2/
MSH6 in 6 cases, MSH2 in one, MSH6 in two, and MLH1/
PMS2 in two cases. Concordant loss of the same MMR
protein was observed in the patient who had developed
multiple synchronous tumors (table 1). This frequency of
immunohistochemical loss of expression in MSI-high
tumors is similar to that previously reported (table 2) and
thus demonstrates that loss of immunostaining for at least
one of the MMR proteins investigated is found in about
85% of MSI-high UUC [18,23]. Regarding histological
grade and stage among the tumors with MSI and/or MMR
protein expression loss, the majority of the tumors were
moderate differentiated (WHO-grade 2–3) and of early
stages (table 1).
Synchronous/metachronous tumor development is com-
mon in urothelial cancer, mainly through intraepithelial
migration or intraluminal dispersion of tumor cells [30].
In our series, 54/216 (25%) patients had developed met-
achronous bladder tumors. An increased incidence of
metachronous tumors has been observed in patients with
MMR defective UUC [19], and synchronous UUC is found
in 1–2% of UUC patients [31]. Of the 8 patients with
MMR defective tumors in our study, 5 had developed
other malignant tumors, including two cancers of the uri-
nary bladder, one colon cancer, one rectal cancer, one
endometrial cancer, one cervical cancer, one soft tissue
sarcoma, and one patient who had developed myelofibro-
sis (table 1). Among these tumors, 5 could be retrieved
and were immunohistochemically stained. The leiomy-
osarcoma, the colon tumor, the endometrial cancer and 2
bladder tumors showed loss of expression for MSH2/
MSH6, which suggests an association with HNPCC.
About 1/3 of HNPCC patients develop metachronous
primary tumors, and the concordant MSI and loss of MMR
protein expression in these cases strongly suggests
HNPCC, although mutation analysis was not performed.
The lifetime risk of developing UUC in HNPCC mutation
carriers is estimated to be 4–10%, and UUC is in the
revised Amsterdam criteria considered to be a HNPCC-
associated tumor type, and screening for UUC is generally
recommended in HNPCC-families (http://www.insight-
group.org), with sonogrophy and urinary analysis. None
of the patients in this series with MSI and/or IHC loss of
MMR protein expression are previously known HNPCC
patients in our health care region. Mutation analysis is not
planned. A higher frequency of extraintestinal tumors has
been reported in families with germline mutations in
MSH2, and from the data available, MSH2 seems to play
a predominant role also in UUC; loss of MSH2 expression
has been reported in 33–60% of MSI-high UUC tumors
[18,19,32,33]. Although our data suggest that MMR
defects represent a minor tumorigenic pathway in the
development of UUC, the high frequency of MSH2/MSH6
loss in MMR-defective tumors should caution clinicians to
obtain an individual and a family history of cancer in
patients with carcinomas of the renal pelvis and the
ureter.
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